Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect
- 1 March 1994
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 45 (3) , 667-671
- https://doi.org/10.1038/ki.1994.89
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.Journal of Clinical Investigation, 1993
- Development of iron-chelating agents for clinical use [editorial; comment]Blood, 1992
- Intracranial complications of mucormycosis: An experimental model and clinical reviewThe Laryngoscope, 1992
- Deferoxamine Therapy and Mucormycosis in Dialysis Patients: Report of an International RegistryAmerican Journal of Kidney Diseases, 1991
- Rhizoferrin ? a novel siderophore from the fungusRhizopus microsporus var.rhizopodiformisBioMetals, 1991
- Effects of iron and desferrioxamine on Rhizopus infectionMycopathologia, 1990
- Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis)Kidney International, 1989
- Oral iron chelators: Prospects for future developmentEuropean Journal of Haematology, 1989
- Optimisation of hybridoma cell growth and monoclonal antibody secretion in a chemically defined, serum- and protein-free culture mediumJournal of Immunological Methods, 1989
- Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilizationBiochemical Pharmacology, 1985